Israeli SleepX to be merged into AppYea Inc. (APYP)
A revolutionary AI approach to the problem of snoring
Nevada, Sept 8, 2021. AppYea continues the process of merging SleepX into the company. The merger is expected to be completed by 12/01/2021 in accordance with the model published on 08/02/2021.
Following the update on 02/23/2021, a final payment was made to the University as part of a patent rights license agreement.
Filed on August 10, 2021: Reply to exam report IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
For: APPARATUS AND METHOD FOR DIAGNOSING SLEEP QUALITY
Appl. No. 14/404,621
APYP Merger News:
AppYea, Inc. and SleepX Ltd. Agree to Securities Exchange Agreement.
New York, NY, August 02, 2021 (GLOBE NEWSWIRE) -- AppYea, Inc. (OTCPINK: APYP) announced today that it has entered into a Securities Exchange Agreement with SleepX Ltd., an Israeli company ("SleepX") and the shareholders of SleepX pursuant to which SleepX would become a wholly-owned subsidiary of APYP, and the shareholders of SleepX would receive such number of shares of common stock of APYP as described below. Continue reading...
AppYea, Inc has been correcting during the last five days, but the OTC stock is on track to become a major winner in the coming months. The share price fell 44% to $0.0041 and is likely to find strong support at $0.0037. The price hit $0.0077 on July 9, getting close to February’s one cent, which remains the highest level year-to-date (YTD) and since 2015. Still, the long-term bull run is only making its first steps.
The global sleep apnea devices market size was valued at USD 3.7 billion in 2020 and is expected to expand at a compound annual growth rate of 6.2% from 2021 to 2028. Sleep apnea is a sleeping disorder, characterized by irregular breathing, thus providing insufficient oxygen to the brain. According to an American Sleep Association study published in 2020, an estimated 50 million to 70 million people in the U.S. are suffering from some form of sleep disorders. Moreover, according to Canadian Respiratory Journal in 2014, around 5.4 million adults in Canada were diagnosed with sleep apnea or were at higher risk of developing OSA. According to a study conducted by ResMed in 2018, around 175 million people in Europe were suffering from sleep apnea. Continue reading...
Paid 60% of the payment for the University's Patent License Agreement.
Examines an engagement with a leading law firm specializing in patent litigation and intellectual property protection. Vew our IP portfolio
Advancing to next stage! Click to see the public disclosure
Following the public disclosure of the LOI amongst our companies and APPYA Inc. (OTCPINK: APYP),
we are pleased to announce that we have reached preliminary understandings on the principal terms of the acquisition and are working towards it.
We believe that the acquisition should provide significant value for all parties and allow the DreamIT X3, our principal anti-snoring product, to reach the market as early as the first half of 2022 under the “Wellness Gadgets” category, which will allow for a shorter time for the market.
We believe that there is a pressing need for the device. According to the American National Sleep Foundation in the United States, 57% of men and 40% of women suffer from chronic snoring https://www.sleepfoundation.org/snoring
DreamIT X3 is based on a unique technology that is patents protected and is a revolutionary solution to snoring. We believe the unit retael price should not exced $149.
We are excited to begin working with our US strategic partners to realize our business vision!